Protocol Ledger

NCT04526899 · Phase II · COMPLETED

A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

Interventional Phase II clinical trial protocol NCT04526899 sponsored by BioNTech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-19 Enrollment: 184 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04526899
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)184 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04526899
Protocol FieldVerified Registry Value
NCT IdentifierNCT04526899
Consolidated Lead SponsorBioNTech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment184 participants (ACTUAL)
Registered Start Date2021-05-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04526899
Hospital Research SiteLocationSite Profile
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CAOpen Hospital Dossier ->
Universitätsklinikum HeidelbergHeidelberg, GermanyOpen Hospital Dossier ->
Universitätsklinikum LeipzigLeipzig, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI